Effects/NNS
of/IN
intranasal/JJ
glucocorticoids/NNS
on/IN
endogenous/JJ
glucocorticoid/NN
peripheral/JJ
and/CC
central/JJ
function/NN
./.

Glucocorticoids/NNS
are/VBP
among/IN
the/DT
most/RBS
potent/JJ
antiinflammatory/JJ
agents/NNS
that/WDT
can/MD
be/VB
used/VBN
in/IN
the/DT
treatment/NN
of/IN
rhinitis/NN
./.
=====
Their/PRP$
mechanisms/NNS
of/IN
action/NN
are/VBP
multiple/JJ
and/CC
complex/JJ
and/CC
a/DT
number/NN
of/IN
reports/NNS
describe/VBP
significant/JJ
systemic/JJ
effects/NNS
of/IN
locally/RB
administered/VBN
glucocorticoids/NNS
./.
=====
In/IN
order/NN
to/TO
evaluate/VB
the/DT
short-term/JJ
systemic/JJ
effects/NNS
of/IN
intranasally/RB
administered/VBN
glucocorticoids/NNS
,/,
14/CD
normal/JJ
healthy/JJ
subjects/NNS
were/VBD
treated/VBN
with/IN
two/CD
doses/NNS
of/IN
either/CC
budesonide/NN
(/(
BUD/NN
)/)
or/CC
fluticasone/NN
propionate/NN
(/(
FP/NN
)/)
for/IN
2/CD
weeks/NNS
./.
=====
Before/IN
treatment/NN
,/,
at/IN
regular/JJ
intervals/NNS
during/IN
the/DT
treatment/NN
,/,
1/CD
week/NN
and/CC
finally/RB
6/CD
weeks/NNS
after/IN
termination/NN
of/IN
treatment/NN
,/,
the/DT
effects/NNS
on/IN
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
and/CC
methallothionein/NN
(/(
MTIIa/NN
)/)
mRNA/NN
expression/NN
levels/NNS
were/VBD
examined/VBN
in/IN
peripheral/JJ
lymphocytes/NNS
using/VBG
a/DT
solution/NN
hybridization/NN
assay/NN
./.
=====
Serum/NN
cortisol/NN
,/,
osteocalcin/NN
and/CC
urinary/JJ
cortisol/NN
levels/NNS
were/VBD
also/RB
determined/VBN
./.
=====
An/DT
insulin/NN
tolerance/NN
test/NN
(/(
ITT/NN
)/)
was/VBD
performed/VBN
at/IN
the/DT
end/NN
of/IN
the/DT
second/JJ
week/NN
of/IN
treatment/NN
and/CC
at/IN
the/DT
end/NN
of/IN
the/DT
6-week/JJ
washout/NN
period/NN
with/IN
no/DT
statistically/RB
significant/JJ
change/NN
in/IN
cortisol/NN
response/NN
./.
=====
In/IN
peripheral/JJ
lymphocytes/NNS
,/,
GR/NN
mRNA/NN
levels/NNS
were/VBD
significantly/RB
down-regulated/VBN
./.
=====
MTIIa/NN
mRNA/NN
levels/NNS
increased/VBD
significantly/RB
./.
=====
Serum/NN
osteocalcin/NN
decreased/VBD
significantly/RB
during/IN
treatment/NN
with/IN
both/CC
BUD/NN
and/CC
FP/NN
./.
=====
Serum/NN
cortisol/NN
decreased/VBD
after/IN
1/CD
week/NN
of/IN
treatment/NN
whereas/IN
urinary/JJ
cortisol/NN
was/VBD
not/RB
affected/VBN
until/IN
the/DT
second/JJ
week/NN
of/IN
treatment/NN
./.
=====
In/IN
conclusion/NN
,/,
intranasal/JJ
glucocorticoids/NNS
at/IN
clinically/RB
recommended/VBN
doses/NNS
have/VBP
not/RB
only/RB
significant/JJ
systemic/JJ
effects/NNS
on/IN
adrenal/JJ
function/NN
,/,
but/CC
also/RB
have/VBP
an/DT
effect/NN
on/IN
specific/JJ
gene/NN
expression/NN
in/IN
peripheral/JJ
lymphocytes/NNS
./.
=====
These/DT
effects/NNS
are/VBP
receptor-dependent/JJ
,/,
reversible/JJ
,/,
and/CC
according/VBG
to/TO
serum/NN
and/CC
urinary/JJ
cortisol/NN
levels/NNS
and/CC
ITT/NN
,/,
leave/VBP
the/DT
hypothalamic-pituitary-adrenal/JJ
function/NN
intact/JJ
./.
=====
Finally/RB
,/,
these/DT
short-term/JJ
systemic/JJ
effects/NNS
were/VBD
not/RB
associated/VBN
with/IN
any/DT
of/IN
the/DT
noticeable/JJ
side-effects/NNS
usually/RB
observed/VBN
during/IN
long-term/JJ
treatment/NN
with/IN
glucocorticoids/NNS
./.